Perrigo Company plc

Equities

PRGO

IE00BGH1M568

Market Closed - Nyse Other stock markets 04:00:02 2026-01-15 pm EST			5-day change	1st Jan Change
15.17 ^USD	+2.09%		+3.98%	+8.98%

Jan. 12	Ansell Limited Announces Appointment of Ansell Limited as Independent Non-Executive Director , with Effect on March 1, 2026	CI
Dec. 21	Perrigo Company plc(NYSE:PRGO) added to S&P 600 Health Care	CI

Transcript : Perrigo Company plc, Q3 2025 Earnings Call, Nov 05, 2025

Published on 11/05/2025 at 10:21 am EST - Modified on 11/05/2025 at 11:21 am EST

S&P Capital IQ

Presentation Operator Message
Operator (Operator)

Good morning, ladies and gentlemen, and welcome to Perrigo Q3 2025 Financial Results Conference Call. [Operator Instructions] This call is being

This article is reserved for subscribers

Unlock the article : SUBSCRIBE!

Already a customer? Log In

Latest news about Perrigo Company plc

Jan. 12	Ansell Limited Announces Appointment of Ansell Limited as Independent Non-Executive Director , with Effect on March 1, 2026	CI
Dec. 21	Perrigo Company plc(NYSE:PRGO) added to S&P 600 Health Care	CI
Dec. 21	Perrigo Company plc(NYSE:PRGO) added to S&P 600	CI
Dec. 21	Perrigo Company plc(NYSE:PRGO) dropped from S&P 400 Health Care	CI
Dec. 21	Perrigo Company plc(NYSE:PRGO) dropped from S&P 400	CI
Nov. 06	Perrigo to Conduct Strategic Review of Its Infant Formula Business	CI
Nov. 06	Perrigo Shares Fall After JPMorgan Downgrade	MT
Nov. 06	The Market Can't Make Up Its Mind
Nov. 06	JPMorgan Downgrades Perrigo to Neutral From Overweight, Adjusts Price Target to $20 From $32	MT
Nov. 05	Perrigo's Fiscal Q3 Adjusted Earnings, Sales Decline; Fiscal 2025 Outlook Lowered; Shares Fall	MT
Nov. 05	Perrigo Company plc Updates Earnings Guidance for the Full Year of 2025	CI
Nov. 05	Perrigo Company plc, Q3 2025 Earnings Call, Nov 05, 2025
Nov. 05	Perrigo Launching Strategic Review of Infant Formula Business	MT
Nov. 05	Perrigo begins strategic review of baby formula business	RE
Nov. 05	Perrigo Company plc Reports Earnings Results for the Third Quarter and Nine Months Ended September 27, 2025	CI
Nov. 05	Perrigo's Fiscal Q3 Adjusted Earnings, Sales Decline; Fiscal 2025 Outlook Lowered	MT
Nov. 05	(PRGO) Perrigo Expects Full Year 2025 Adjusted EPS Range $2.70 - $2.80, vs. FactSet Est of $2.97	MT
Nov. 05	Perrigo Q3 net sales miss estimates	RE
Nov. 05	Earnings Flash (PRGO) Perrigo Company plc Reports Q3 Revenue $1.04B, vs. FactSet Est of $1.10B	MT
Nov. 05	Earnings Flash (PRGO) Perrigo Company plc Posts Q3 Adjusted EPS $0.80 per Share, vs. FactSet Est of $0.76	MT
Oct. 31	Drugmakers must face skincare drug price-fixing lawsuit, US judge rules	RE
25-10-29	Perrigo Company plc Declares Quarterly Dividend, Payable on December 16, 2025	CI
25-10-29	Perrigo Keeps Quarterly Dividend at $0.29 a Share, Payable Dec. 16 to Shareholders of Record on Nov. 28	MT
25-10-09	Perrigo Company plc Announces Opill®? Partners with Self-Care Brand Chillhouse to Launch 'Opill and Chill'	CI
25-09-18	Teamsters says local 210 members at Perrigo's Bronx production facility ratified new 3-year contract	RE